Related Experiment Video
Updated: May 10, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
The role of epigenetics in malignant pleural mesothelioma
Fabian Vandermeers1, Sathya Neelature Sriramareddy1, Chrisostome Costa1
1Molecular and Cellular Epigenetics (GIGA-Cancer) and Molecular Biology (GxABT), University of Liège (ULg), Liège, Belgium.
Abstract:
Malignant pleural mesothelioma (MPM) is an almost invariably fatal cancer of the pleura due to asbestos exposure. Increasing evidence indicates that unresponsiveness to chemotherapy is due to epigenetic errors leading to inadequate gene expression in tumor cells. The availability of compounds that modulate epigenetic modifications, such as histone acetylation or DNA methylation, offers new prospects for treatment of MPM. Here, we review latest findings on epigenetics in mesothelioma and present novel strategies for promising epigenetic therapies.
Insights
Malignant pleural mesothelioma (MPM) is a fatal cancer linked to asbestos. Epigenetic errors cause chemotherapy resistance, but new epigenetic therapies targeting these changes show promise for treating MPM.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Malignant pleural mesothelioma (MPM) is a fatal cancer primarily caused by asbestos exposure.
- Chemotherapy resistance in MPM is increasingly linked to epigenetic alterations affecting gene expression.
- Epigenetic modifications, including histone acetylation and DNA methylation, are key regulatory mechanisms in cancer.
Purpose of the Study:
- To review recent advancements in understanding epigenetics in mesothelioma.
- To explore novel epigenetic therapy strategies for MPM treatment.
- To highlight the potential of targeting epigenetic errors for improved MPM outcomes.
Main Methods:
- Literature review of recent findings on epigenetics in mesothelioma.
- Analysis of current and emerging epigenetic therapeutic compounds.
- Synthesis of evidence linking epigenetic modifications to MPM pathogenesis and treatment response.
Main Results:
- Epigenetic dysregulation is a significant factor in MPM development and chemoresistance.
- Compounds modulating histone acetylation and DNA methylation are emerging as promising therapeutic agents.
- Targeting epigenetic errors offers a novel approach to overcome treatment unresponsiveness in MPM.
Conclusions:
- Epigenetic therapies represent a promising frontier for treating malignant pleural mesothelioma.
- Further research into epigenetic mechanisms and targeted interventions is crucial for improving patient survival.
- Modulating epigenetic modifications holds potential to overcome chemotherapy resistance in MPM.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Pleural Disorders: Types and Brief Description
Mitogens and the Cell Cycle
Induced Pluripotent Stem Cells
Somatic cells are...

